[
  {
    "ts": null,
    "headline": "Fidelity Strategic Dividend & Income Fund Q2 2025 Commentary",
    "summary": "Fidelity Investments highlights strong Q2 gains in convertibles and infrastructure. See how tactical shifts shaped results. Explore the full fund update.",
    "url": "https://finnhub.io/api/news?id=da9a47446368a5deb2b7e49b3d1fb01a4272e75100efada772f083753847fbea",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753477200,
      "headline": "Fidelity Strategic Dividend & Income Fund Q2 2025 Commentary",
      "id": 136092631,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1303853966/image_1303853966.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Fidelity Investments highlights strong Q2 gains in convertibles and infrastructure. See how tactical shifts shaped results. Explore the full fund update.",
      "url": "https://finnhub.io/api/news?id=da9a47446368a5deb2b7e49b3d1fb01a4272e75100efada772f083753847fbea"
    }
  },
  {
    "ts": null,
    "headline": "Metastatic Hormone Refractory Prostate Cancer Pipeline Market Research Report 2025 | In-depth Analysis of 180+ Companies and Over 200 Drugs in Development",
    "summary": "The report details drug profiles and phases, highlighting key players like Lantheus, Merck, and Pfizer, with a focus on novel therapeutic strategies and ongoing research.Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The \"Metastatic Hormone Refractory Prostate Cancer - Pipeline Insight, 2025\" has been added to ResearchAndMarkets.com's offering. The \"Metastatic Hormone Refractory Prostate Cancer - Pipeline Insight, 2025\" report offers an in-depth analysis of over 180 companies and 200 pipeline drugs i",
    "url": "https://finnhub.io/api/news?id=7452b499d0c3719687d1903078042bd19778b4caf6c422c2fe49c10668049685",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753454400,
      "headline": "Metastatic Hormone Refractory Prostate Cancer Pipeline Market Research Report 2025 | In-depth Analysis of 180+ Companies and Over 200 Drugs in Development",
      "id": 136088617,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The report details drug profiles and phases, highlighting key players like Lantheus, Merck, and Pfizer, with a focus on novel therapeutic strategies and ongoing research.Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The \"Metastatic Hormone Refractory Prostate Cancer - Pipeline Insight, 2025\" has been added to ResearchAndMarkets.com's offering. The \"Metastatic Hormone Refractory Prostate Cancer - Pipeline Insight, 2025\" report offers an in-depth analysis of over 180 companies and 200 pipeline drugs i",
      "url": "https://finnhub.io/api/news?id=7452b499d0c3719687d1903078042bd19778b4caf6c422c2fe49c10668049685"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to watch next week: Microsoft, Apple, Shell, AstraZeneca and HSBC",
    "summary": "Earnings preview of key companies reporting in the coming week and what to look out for.",
    "url": "https://finnhub.io/api/news?id=675d305c685a59b79d1453c7382d6ed52d84d8edd73e7259243df69108a0ab3c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753454192,
      "headline": "Stocks to watch next week: Microsoft, Apple, Shell, AstraZeneca and HSBC",
      "id": 136088416,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Earnings preview of key companies reporting in the coming week and what to look out for.",
      "url": "https://finnhub.io/api/news?id=675d305c685a59b79d1453c7382d6ed52d84d8edd73e7259243df69108a0ab3c"
    }
  },
  {
    "ts": null,
    "headline": "Apple, Amazon, Meta Highlight Earnings Calendar; S&P 500 Titan Sets Up Ahead Of Results",
    "summary": "The earnings season gets into full swing with four Magnificent Seven leaders on deck, including Apple, while a handful of other Dow Jones stocks also highlight the upcoming week's earnings calendar.  Apple and Amazon follow on Thursday.",
    "url": "https://finnhub.io/api/news?id=da33fd804226a184af4c25580e27decf1617920399a0ecaf08f0b024fc9a51cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753452457,
      "headline": "Apple, Amazon, Meta Highlight Earnings Calendar; S&P 500 Titan Sets Up Ahead Of Results",
      "id": 136088419,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The earnings season gets into full swing with four Magnificent Seven leaders on deck, including Apple, while a handful of other Dow Jones stocks also highlight the upcoming week's earnings calendar.  Apple and Amazon follow on Thursday.",
      "url": "https://finnhub.io/api/news?id=da33fd804226a184af4c25580e27decf1617920399a0ecaf08f0b024fc9a51cc"
    }
  },
  {
    "ts": null,
    "headline": "Saudi Arabia IVF Market Outlook Report 2025-2033 | Rising Infertility, Medical Advances, Government Supports and Societal Shifts Driving Growth",
    "summary": "The Saudi Arabia IVF market is projected to grow from $306.59 million in 2024 to $522.39 million by 2033, driven by a 6.10% CAGR. Factors like rising infertility rates, delayed parenthood, technological advancements, and supportive government initiatives contribute to this growth. The market segments into procedure types, instruments, and end-users. Notable players include FUJIFILM Holdings and Merck & Co. Despite growth, challenges like high treatment costs and cultural sensitivities persist. R",
    "url": "https://finnhub.io/api/news?id=0913c7ca1544b2c95b298225c72429c7eaf92d27d22e7ae0a0256898d70994e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753448880,
      "headline": "Saudi Arabia IVF Market Outlook Report 2025-2033 | Rising Infertility, Medical Advances, Government Supports and Societal Shifts Driving Growth",
      "id": 136088620,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Saudi Arabia IVF market is projected to grow from $306.59 million in 2024 to $522.39 million by 2033, driven by a 6.10% CAGR. Factors like rising infertility rates, delayed parenthood, technological advancements, and supportive government initiatives contribute to this growth. The market segments into procedure types, instruments, and end-users. Notable players include FUJIFILM Holdings and Merck & Co. Despite growth, challenges like high treatment costs and cultural sensitivities persist. R",
      "url": "https://finnhub.io/api/news?id=0913c7ca1544b2c95b298225c72429c7eaf92d27d22e7ae0a0256898d70994e9"
    }
  },
  {
    "ts": null,
    "headline": "Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?",
    "summary": "MRK is gearing up to report Q2 earnings. While Keytruda drives growth, there are concerns over Gardasil's China sales, generics and pipeline depth.",
    "url": "https://finnhub.io/api/news?id=1a11fa68511ce3ca5dea038d93da8503061e72b3a72de7fccc03971642b74def",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753446420,
      "headline": "Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?",
      "id": 136088621,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MRK is gearing up to report Q2 earnings. While Keytruda drives growth, there are concerns over Gardasil's China sales, generics and pipeline depth.",
      "url": "https://finnhub.io/api/news?id=1a11fa68511ce3ca5dea038d93da8503061e72b3a72de7fccc03971642b74def"
    }
  },
  {
    "ts": null,
    "headline": "U.S. Keytruda Market Research Report 2025 | Merck's Keytruda Faces Challenges as Patent Expiry Approaches in 2028 - Forecast to 2033",
    "summary": "The U.S. Keytruda market, valued at $17.87 billion in 2024, faces a projected CAGR decline of -3.12% by 2033 due to patent expiration and biosimilar competition. Keytruda's continued use in various cancer treatments, including melanoma and lung cancer, alongside innovations and new trial results, aim to mitigate these challenges and sustain market presence.Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The \"U.S. Keytruda Market Size, Share & Trends Analysis Report By Application (Lung Cancer, Breast",
    "url": "https://finnhub.io/api/news?id=9f9b29c47638785230af8e6eaf92668f3e602f700adfd39c130437b50902346d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753435500,
      "headline": "U.S. Keytruda Market Research Report 2025 | Merck's Keytruda Faces Challenges as Patent Expiry Approaches in 2028 - Forecast to 2033",
      "id": 136084960,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The U.S. Keytruda market, valued at $17.87 billion in 2024, faces a projected CAGR decline of -3.12% by 2033 due to patent expiration and biosimilar competition. Keytruda's continued use in various cancer treatments, including melanoma and lung cancer, alongside innovations and new trial results, aim to mitigate these challenges and sustain market presence.Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The \"U.S. Keytruda Market Size, Share & Trends Analysis Report By Application (Lung Cancer, Breast",
      "url": "https://finnhub.io/api/news?id=9f9b29c47638785230af8e6eaf92668f3e602f700adfd39c130437b50902346d"
    }
  },
  {
    "ts": null,
    "headline": "Post-Operative Nausea and Vomiting Market Report 2025: Surge in Surgical Procedures Fuels $2.97 Billion Growth in PONV Market by 2029",
    "summary": "Post-operative nausea and vomiting (PONV) market to rise from $2.11B in 2024 to $2.97B in 2029, driven by innovations in antiemetic therapies, personalized medicine, and digital health technologies. Key players include Pfizer, Merck, and Novartis. North America leads, but Asia-Pacific grows fastest. Post-Operative Nausea and Vomiting Market Post-Operative Nausea and Vomiting Market Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The \"Post-Operative Nausea and Vomiting Market Report 2025\" report has be",
    "url": "https://finnhub.io/api/news?id=5df47ee56a56a6522a21a487dd2e7cf6da6a4423dca6fd0652f5d6b84ee9651c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753430580,
      "headline": "Post-Operative Nausea and Vomiting Market Report 2025: Surge in Surgical Procedures Fuels $2.97 Billion Growth in PONV Market by 2029",
      "id": 136084961,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Post-operative nausea and vomiting (PONV) market to rise from $2.11B in 2024 to $2.97B in 2029, driven by innovations in antiemetic therapies, personalized medicine, and digital health technologies. Key players include Pfizer, Merck, and Novartis. North America leads, but Asia-Pacific grows fastest. Post-Operative Nausea and Vomiting Market Post-Operative Nausea and Vomiting Market Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The \"Post-Operative Nausea and Vomiting Market Report 2025\" report has be",
      "url": "https://finnhub.io/api/news?id=5df47ee56a56a6522a21a487dd2e7cf6da6a4423dca6fd0652f5d6b84ee9651c"
    }
  },
  {
    "ts": null,
    "headline": "UBS Bullish on Merck (MRK) Following Verona Pharma Purchase",
    "summary": "Merck & Co., Inc. (NYSE:MRK) ranks among the best magic formula stocks to invest in. On July 10, UBS reiterated its Buy rating and $105 price target for Merck & Co., Inc. (NYSE:MRK). Analyst Trung Huynh remained optimistic about the pharmaceutical giant after Merck confirmed that it would acquire London-based Verona Pharma for $10 billion. […]",
    "url": "https://finnhub.io/api/news?id=91cfb6e999635d3002cba419166ed2b6ea38d7abe56d4804a3d3c0b3c9e0c2f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753415364,
      "headline": "UBS Bullish on Merck (MRK) Following Verona Pharma Purchase",
      "id": 136084962,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) ranks among the best magic formula stocks to invest in. On July 10, UBS reiterated its Buy rating and $105 price target for Merck & Co., Inc. (NYSE:MRK). Analyst Trung Huynh remained optimistic about the pharmaceutical giant after Merck confirmed that it would acquire London-based Verona Pharma for $10 billion. […]",
      "url": "https://finnhub.io/api/news?id=91cfb6e999635d3002cba419166ed2b6ea38d7abe56d4804a3d3c0b3c9e0c2f7"
    }
  }
]